FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to peptide analogues of oxyintomoduline (OXM, glucagon-37), which can be modified for providing the stability of cleavage and inactivation with dipeptidyl peptidase IV (DPP-IV) for increasing a half-life time in vivo of the peptide analogue alongside with enabling the peptide analogue acting as a double agonist GLP-1/glucagon receptor (GCGR).
EFFECT: peptide analogues are applicable for treating metabolic disorders, such as diabetes and obesity.
16 cl, 16 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY | 2013 |
|
RU2671088C2 |
| COMPOSITION FOR HYPERLIPIDEMIA TREATMENT CONTAINING OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2642267C2 |
| GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS | 2008 |
|
RU2477286C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| CONJUGATE, CONTAINING OXYNTOMODULIN AND FRAGMENT OF IMMUNOGLOBULIN, AND USE THEREOF | 2012 |
|
RU2607365C2 |
